Piper Sandler Reiterates Overweight on Sutro Biopharma, Maintains $11 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Edward Tenthoff has reiterated an Overweight rating on Sutro Biopharma (NASDAQ:STRO) and maintained a price target of $11.
October 11, 2024 | 5:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler has reiterated an Overweight rating on Sutro Biopharma, maintaining a price target of $11, indicating confidence in the company's potential.
The reiteration of an Overweight rating and maintenance of a price target by a reputable analyst suggests a positive outlook for Sutro Biopharma. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100